ERBB2 and collecting duct carcinoma: To the best of our knowledge, the only three studies that tried to characterize HER2 in CDC include a retrospective study conducted in 11 CDC cases in which HER2 amplification evaluated by competitive PCR, was present in 5 out of 11 cases (45%) and all these patients with HER2 amplified died within one year [24].